HTG Molecular Diagnostics, Inc. Deferred Tax Assets, in Process Research and Development
HTG Molecular Diagnostics, Inc. had Deferred Tax Assets, in Process Research and Development of $2.00 million as of 2022-12-31, per its 10-K filed 2023-03-30.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment · last filed 2023-03-30
- 2022-12-31: Deferred Tax Assets, in Process Research and Development $2.00M.
- 2021-12-31: Deferred Tax Assets, in Process Research and Development $0.00.
- 2015-12-31: Deferred Tax Assets, in Process Research and Development $27.58K.
- 2014-12-31: Deferred Tax Assets, in Process Research and Development $55.35K.
| Period end | Deferred Tax Assets, in Process Research and Development |
|---|---|
| 2022-12-31 | $2.00M 10-K · filed 2023-03-30 |
| 2021-12-31 | $0.00 10-K · filed 2023-03-30 |
| 2015-12-31 | $27.58K 10-K · filed 2017-03-23 |
| 2014-12-31 | $55.35K 10-K · filed 2016-03-25 |